The introduction of tyrosine kinase inhibitors (TKIs), such as imatinib, that target the BCR-ABL oncoprotein has revolutionized CML therapy.32 This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.